Operaciones Marinus Pharmaceuticals, Inc. - MRNS CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Diferencial | 0.07 | ||||||||
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
Horario tarifa nocturna | 21:00 (UTC) | ||||||||
Cantidad comercializada mínima | 1 | ||||||||
Divisa | USD | ||||||||
Margen | 20% | ||||||||
Mercado de valores | United States of America | ||||||||
Comisión por operación | 0% |
*Information provided by Capital.com
Marinus Pharmaceuticals Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Cierre previo* | 7.62 |
Abrir* | 7.84 |
Cambio de 1 año* | -3.33% |
Rango del día* | 7.55 - 8.11 |
Rango de 52 semanas | 3.47-9.82 |
Volumen medio (10 días) | 751.36K |
Volumen medio (3 meses) | 13.83M |
Capitalización de mercado | 377.59M |
Ratio P/E | -100.00K |
Acciones en circulación | 50.55M |
Ingresos | 21.67M |
EPS | -0.56 |
Dividendo (Rendimiento %) | N/A |
Beta | 1.16 |
Próxima fecha de resultados | Aug 9, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Cierre | Change | Change (%) | Apertura | High | Low |
---|---|---|---|---|---|---|
Jun 6, 2023 | 7.62 | 0.39 | 5.39% | 7.23 | 7.70 | 7.23 |
Jun 5, 2023 | 7.43 | 0.05 | 0.68% | 7.38 | 7.46 | 7.17 |
Jun 2, 2023 | 7.35 | 0.14 | 1.94% | 7.21 | 7.49 | 7.10 |
Jun 1, 2023 | 7.18 | 0.13 | 1.84% | 7.05 | 7.25 | 6.92 |
May 31, 2023 | 7.06 | 0.04 | 0.57% | 7.02 | 7.25 | 6.98 |
May 30, 2023 | 7.22 | 0.18 | 2.56% | 7.04 | 7.42 | 6.92 |
May 26, 2023 | 7.04 | 0.09 | 1.29% | 6.95 | 7.07 | 6.75 |
May 25, 2023 | 6.99 | -0.51 | -6.80% | 7.50 | 7.69 | 6.96 |
May 24, 2023 | 7.64 | 0.10 | 1.33% | 7.54 | 7.81 | 7.40 |
May 23, 2023 | 7.70 | 0.00 | 0.00% | 7.70 | 7.89 | 7.58 |
May 22, 2023 | 7.73 | -0.23 | -2.89% | 7.96 | 8.24 | 7.66 |
May 19, 2023 | 8.10 | 0.02 | 0.25% | 8.08 | 8.37 | 7.96 |
May 18, 2023 | 8.09 | -0.08 | -0.98% | 8.17 | 8.37 | 7.99 |
May 17, 2023 | 8.27 | -0.24 | -2.82% | 8.51 | 8.68 | 8.19 |
May 16, 2023 | 8.49 | -0.03 | -0.35% | 8.52 | 8.52 | 8.41 |
Marinus Pharmaceuticals, Inc. Events
Hora (UTC) (UTC) | País | Evento |
---|---|---|
Wednesday, August 9, 2023 | ||
Hora (UTC) (UTC) 12:30 | País US
| Evento Q2 2023 Marinus Pharmaceuticals Inc Earnings Release Q2 2023 Marinus Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Monday, November 6, 2023 | ||
Hora (UTC) (UTC) 10:59 | País US
| Evento Q3 2023 Marinus Pharmaceuticals Inc Earnings Release Q3 2023 Marinus Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos totales | 25.478 | 15.345 | 1.718 | 0 | 0 |
Gastos totales de explotación | 139.066 | 112.476 | 69.655 | 54.422 | 37.179 |
Gastos de venta/general/administración Gastos, total | 56.845 | 37.278 | 18.549 | 11.456 | 8.785 |
Investigación y desarrollo | 79.912 | 73.52 | 51.106 | 42.966 | 28.394 |
Ingresos de explotación | -113.588 | -97.131 | -67.937 | -54.422 | -37.179 |
Ingresos por intereses (gastos), netos No operativos | -8.318 | -2.502 | 0.499 | 0.354 | 0.454 |
Otros, netos | -1.896 | 0.857 | -0.037 | -0.053 | -0.001 |
Ingresos netos antes de impuestos | -16.427 | -98.776 | -67.475 | -54.121 | -36.726 |
Ingresos netos después de impuestos | -19.816 | -98.776 | -67.475 | -54.121 | -36.726 |
Beneficio neto antes de partidas extra. Elementos | -19.816 | -98.776 | -67.475 | -54.121 | -36.726 |
Ingresos netos | -19.816 | -98.776 | -67.475 | -54.121 | -36.726 |
Total Adjustments to Net Income | 0 | -8.88 | |||
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -19.816 | -98.776 | -76.355 | -54.121 | -36.726 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -19.816 | -98.776 | -76.355 | -54.121 | -36.726 |
Beneficio neto diluido | -19.816 | -98.776 | -76.355 | -54.121 | -36.726 |
Promedio ponderado de acciones diluidas | 39.0726 | 36.6972 | 27.2701 | 13.6282 | 10.2239 |
BPA diluido sin partidas extraordinarias | -0.50716 | -2.69165 | -2.79996 | -3.97125 | -3.59219 |
BPA normalizado diluido | -2.28011 | -2.64593 | -2.79996 | -3.97125 | -3.59219 |
Ingresos | 25.478 | 15.345 | 1.718 | ||
Gastos (ingresos) extraordinarios | 0.8 | 1.678 | |||
Coste de los ingresos, total | 1.509 | ||||
Beneficio bruto | 23.969 | ||||
Gain (Loss) on Sale of Assets | 107.375 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Ingresos totales | 10.38 | 7.162 | 2.34 | 15.976 | 14.186 |
Ingresos | 10.38 | 7.162 | 2.34 | 15.976 | 14.186 |
Gastos totales de explotación | 43.343 | 37.174 | 32.439 | 69.453 | 30.897 |
Gastos de venta/general/administración Gastos, total | 15.204 | 14.658 | 13.389 | 28.798 | 11.737 |
Investigación y desarrollo | 27.933 | 21.424 | 19.002 | 39.486 | 17.991 |
Ingresos de explotación | -32.963 | -30.012 | -30.099 | -53.477 | -16.711 |
Ingresos por intereses (gastos), netos No operativos | -1.804 | -1.946 | -2.12 | -4.252 | -1.68 |
Otros, netos | 0.037 | -0.717 | -0.114 | -1.065 | -0.97 |
Ingresos netos antes de impuestos | -34.73 | -32.675 | 75.042 | -58.794 | -19.361 |
Ingresos netos después de impuestos | -34.73 | -34.312 | 73.29 | -58.794 | -19.361 |
Beneficio neto antes de partidas extra. Elementos | -34.73 | -34.312 | 73.29 | -58.794 | -19.361 |
Ingresos netos | -34.73 | -34.312 | 73.29 | -58.794 | -19.361 |
Total Adjustments to Net Income | 0.336 | -1.656 | 1.32 | ||
Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -34.73 | -33.976 | 71.634 | -57.474 | -19.361 |
Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -34.73 | -33.976 | 71.634 | -57.474 | -19.361 |
Beneficio neto diluido | -34.73 | -33.976 | 71.634 | -57.474 | -19.361 |
Promedio ponderado de acciones diluidas | 51.7697 | 45.0382 | 37.9105 | 37.1432 | 36.8906 |
BPA diluido sin partidas extraordinarias | -0.67086 | -0.75438 | 1.88956 | -1.54736 | -0.52482 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
BPA normalizado diluido | -0.67086 | -0.74284 | 0.04854 | -1.54736 | -0.52482 |
Gastos (ingresos) extraordinarios | 0.8 | ||||
Coste de los ingresos, total | 0.206 | 0.292 | 0.048 | 1.169 | 1.169 |
Beneficio bruto | 10.174 | 6.87 | 2.292 | 14.807 | 13.017 |
Gain (Loss) on Sale of Assets | 0 | 107.375 | 0 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Activo Corriente | 252.378 | 131.678 | 146.267 | 94.134 | 73.94 |
Efectivo e inversiones a corto plazo | 240.551 | 122.927 | 139.983 | 91.682 | 72.725 |
Efectivo y Equivalentes | 240.551 | 122.927 | 138.509 | 90.943 | 67.727 |
Inversiones a corto plazo | 0 | 1.474 | 0.739 | 4.998 | |
Prepaid Expenses | 5.402 | 5.565 | 4.638 | 2.452 | 1.215 |
Total Assets | 259.518 | 136.84 | 150.462 | 98.842 | 75.234 |
Property/Plant/Equipment, Total - Net | 5.536 | 4.199 | 3.945 | 4.765 | 1.294 |
Property/Plant/Equipment, Total - Gross | 6.99 | 5.593 | 5.077 | 5.577 | 1.904 |
Accumulated Depreciation, Total | -1.454 | -1.394 | -1.132 | -0.812 | -0.61 |
Long Term Investments | 0 | ||||
Other Long Term Assets, Total | 1.604 | 0.963 | 0.25 | -0.057 | |
Total Current Liabilities | 25.017 | 40.566 | 10.729 | 8.031 | 6.909 |
Accounts Payable | 4.461 | 3.126 | 2.211 | 2.763 | 2.472 |
Accrued Expenses | 19.536 | 16.207 | 8.518 | 5.268 | 4.437 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | |||||
Other Current Liabilities, Total | 1.02 | 21.233 | |||
Total Liabilities | 143.518 | 83.354 | 13.263 | 11.073 | 6.909 |
Total Long Term Debt | 71.018 | 40.809 | 0 | 0 | 0 |
Long Term Debt | 71.018 | 40.809 | |||
Other Liabilities, Total | 47.483 | 1.979 | 2.534 | 3.042 | 0 |
Total Equity | 116 | 53.486 | 137.199 | 87.769 | 68.325 |
Common Stock | 0.05 | 0.037 | 0.037 | 0.087 | 0.053 |
Additional Paid-In Capital | 542.428 | 459.852 | 444.622 | 295.056 | 249.727 |
Retained Earnings (Accumulated Deficit) | -430.521 | -410.705 | -311.929 | -235.574 | -181.453 |
Total Liabilities & Shareholders’ Equity | 259.518 | 136.84 | 150.462 | 98.842 | 75.234 |
Total Common Shares Outstanding | 49.6428 | 36.7902 | 36.5785 | 21.6178 | 13.1298 |
Other Equity, Total | 0 | -0.002 | |||
Treasury Stock - Common | 0 | 0 | 0 | 0 | 0 |
Redeemable Preferred Stock | 4.043 | 4.302 | 4.469 | 28.2 | |
Total deudores, neto | 6.348 | 3.186 | 1.646 | ||
Accounts Receivable - Trade, Net | 6.348 | 3.186 | 1.646 | ||
Total Preferred Shares Outstanding | 0.0043 | 0.00458 | 0.00475 | ||
Total Inventory | 0.077 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Activo Corriente | 219.995 | 252.378 | 177.006 | 101.091 | 135.071 |
Efectivo e inversiones a corto plazo | 199.201 | 240.551 | 168.249 | 92.326 | 126.319 |
Efectivo y Equivalentes | 146.904 | 240.551 | 168.249 | 92.326 | 126.319 |
Inversiones a corto plazo | 52.297 | ||||
Total deudores, neto | 11.693 | 6.348 | 3.398 | 3 | 2.489 |
Accounts Receivable - Trade, Net | 11.693 | 6.348 | 3.398 | 3 | 2.489 |
Prepaid Expenses | 9.064 | 5.402 | 5.255 | 5.765 | 6.263 |
Total Assets | 226.817 | 259.518 | 184.841 | 109.377 | 140.81 |
Property/Plant/Equipment, Total - Net | 5.237 | 5.536 | 6.92 | 7.061 | 4.589 |
Other Long Term Assets, Total | 1.585 | 1.604 | 0.915 | 1.225 | 1.15 |
Total Current Liabilities | 21.514 | 25.017 | 21.05 | 23.11 | 19.536 |
Accounts Payable | 4.466 | 4.461 | 1.622 | 3.299 | 4.671 |
Accrued Expenses | 15.727 | 19.536 | 19.428 | 19.811 | 14.865 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 141.732 | 143.518 | 102.837 | 104.574 | 100.405 |
Total Long Term Debt | 71.498 | 71.018 | 70.78 | 70.35 | 69.927 |
Other Liabilities, Total | 48.72 | 47.483 | 11.007 | 11.114 | 10.942 |
Total Equity | 85.085 | 116 | 82.004 | 4.803 | 40.405 |
Redeemable Preferred Stock | 4.043 | 4.043 | 4.043 | 4.043 | 4.302 |
Common Stock | 0.05 | 0.05 | 0.037 | 0.037 | 0.037 |
Additional Paid-In Capital | 546.169 | 542.428 | 474.133 | 470.222 | 466.132 |
Retained Earnings (Accumulated Deficit) | -465.251 | -430.521 | -396.209 | -469.499 | -430.066 |
Total Liabilities & Shareholders’ Equity | 226.817 | 259.518 | 184.841 | 109.377 | 140.81 |
Total Common Shares Outstanding | 49.6651 | 49.6428 | 37.1966 | 37.1992 | 37.1387 |
Total Preferred Shares Outstanding | 0.0043 | 0.0043 | 0.0043 | 0.0043 | 0.00458 |
Long Term Debt | 71.498 | 71.018 | 70.78 | 70.35 | 69.927 |
Treasury Stock - Common | 0 | 0 | 0 | ||
Other Current Liabilities, Total | 1.321 | 1.02 | 0 | 0 | |
Total Inventory | 0.037 | 0.077 | 0.104 | ||
Property/Plant/Equipment, Total - Gross | 6.99 | ||||
Accumulated Depreciation, Total | -1.454 | ||||
Other Equity, Total | 0.074 |
- Anual
- Trimestral
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Ingresos netos/Línea de salida | -19.816 | -98.776 | -67.475 | -54.121 | -36.726 |
Efectivo de actividades de explotación | -112.886 | -55.477 | -60.912 | -48.633 | -27.842 |
Efectivo de actividades de explotación | 0.418 | 0.355 | 0.334 | 0.278 | 0.127 |
Partidas no monetarias | -87.396 | 14.245 | 8.271 | 5.8 | 4.709 |
Intereses pagados en efectivo | 7.892 | 0 | |||
Cambios en el capital circulante | -6.092 | 28.699 | -2.042 | -0.59 | 4.048 |
Efectivo de actividades de inversión | 105.772 | -1.415 | -0.738 | 3.881 | 19.917 |
Gastos de capital | -1.774 | -2.889 | 0 | -0.388 | -0.083 |
Otras partidas de flujo de caja de inversión, total | 107.546 | 1.474 | -0.738 | 4.269 | 20 |
Efectivo procedente de actividades de financiación | 124.738 | 41.31 | 109.216 | 67.968 | 42.121 |
Elementos de flujo de caja de financiación | 29.879 | -0.148 | 42.3 | ||
Emisión (retiro) de acciones, neto | 66.271 | 1.199 | 109.216 | 67.968 | 0.014 |
Emisión (amortización) de deuda, neta | 28.588 | 40.259 | 0 | -0.193 | |
Variación neta de la tesorería | 117.624 | -15.582 | 47.566 | 23.216 | 34.196 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -34.73 | -19.816 | 14.496 | -58.794 | -19.361 |
Cash From Operating Activities | -41.478 | -112.886 | -90.972 | -61.327 | -27.655 |
Cash From Operating Activities | 0.157 | 0.418 | 0.336 | 0.178 | 0.085 |
Non-Cash Items | 5.231 | -87.396 | -93.437 | 9.791 | 5.594 |
Changes in Working Capital | -12.136 | -6.092 | -12.367 | -12.502 | -13.973 |
Cash From Investing Activities | -51.995 | 105.772 | 105.693 | -0.421 | -0.086 |
Capital Expenditures | 0 | -1.774 | -1.682 | -0.421 | -0.086 |
Other Investing Cash Flow Items, Total | -51.995 | 107.546 | 107.375 | 0 | |
Cash From Financing Activities | -0.174 | 124.738 | 30.601 | 31.147 | 31.133 |
Financing Cash Flow Items | -0.174 | 29.879 | 0 | ||
Issuance (Retirement) of Stock, Net | 0 | 66.271 | 1.763 | 1.747 | 1.733 |
Net Change in Cash | -93.647 | 117.624 | 45.322 | -30.601 | 3.392 |
Issuance (Retirement) of Debt, Net | 0 | 28.588 | 28.838 | 29.4 | 29.4 |
Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
---|---|---|---|---|---|---|
Suvretta Capital Management, LLC | Hedge Fund | 9.5578 | 4831261 | 8266 | 2023-03-31 | LOW |
Eventide Asset Management, LLC | Investment Advisor | 6.2776 | 3173197 | 23197 | 2023-03-31 | MED |
Point72 Asset Management, L.P. | Hedge Fund | 6.2376 | 3153000 | -362000 | 2023-03-31 | HIGH |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 6.2317 | 3150000 | 0 | 2023-03-31 | LOW |
Lion Point Capital, L.P. | Hedge Fund | 5.1834 | 2620096 | -1602552 | 2023-03-31 | MED |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.3221 | 2184744 | 192655 | 2023-03-31 | LOW |
Adage Capital Management, L.P. | Hedge Fund | 4.0249 | 2034500 | -18000 | 2023-03-31 | MED |
Bleichroeder LP | Investment Advisor | 3.7043 | 1872463 | 0 | 2023-03-31 | LOW |
Woodline Partners LP | Hedge Fund | 3.1602 | 1597411 | 26019 | 2023-03-31 | HIGH |
Bain Capital Life Sciences Investors, LLC | Investment Advisor | 2.8311 | 1431058 | 0 | 2023-03-31 | LOW |
Sofinnova Investments, Inc | Venture Capital | 2.3748 | 1200389 | 1200389 | 2023-03-31 | MED |
GMT Capital Corp. | Hedge Fund | 2.3375 | 1181570 | 1181570 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.0727 | 1047715 | 25084 | 2023-03-31 | LOW |
Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 2.0294 | 1025835 | 588135 | 2023-03-31 | LOW |
AIGH Capital Management, LLC. | Private Equity | 1.993 | 1007415 | 1007415 | 2023-03-31 | MED |
Millennium Management LLC | Hedge Fund | 1.8414 | 930766 | -151993 | 2023-03-31 | HIGH |
Opaleye Management Inc. | Hedge Fund | 1.5134 | 765000 | -61200 | 2023-03-31 | LOW |
Assenagon Asset Management S.A. | Investment Advisor | 1.3502 | 682491 | 232543 | 2023-03-31 | HIGH |
Medical Strategy GmbH | Investment Advisor | 1.3059 | 660114 | 78604 | 2023-01-31 | LOW |
Barclays Capital Inc. | Research Firm | 1.2212 | 617280 | 599125 | 2023-03-31 | HIGH |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Marinus Pharmaceuticals, Inc. Company profile
Sobre Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc. es una compañía biofarmacéutica en etapa clínica. La Compañía se centra en desarrollar y comercializar productos terapéuticos para tratar la epilepsia y los trastornos neuropsiquiátricos. Su producto candidato en etapa clínica, ganaxolone, es un modulador que se está desarrollando en varias formas de dosis, incluidas intravenosa, cápsulas orales y líquidos orales, destinadas a aportar más opciones de tratamiento a pacientes pediátricos y adultos con enfermedades de atención aguda y crónica. La ganaxolone actúa sobre el receptor GABAA, un objetivo en el cerebro conocido tanto por los efectos anticonvulsivos como contra la ansiedad a través de la modulación alostérica positiva. La Compañía está desarrollando ganaxolone para la epilepsia múltiple y otras indicaciones neuropsiquiátricas, incluida la terapia complementaria, para el tratamiento de las convulsiones de inicio focal resistentes a los medicamentos; estado epiléptico; Síndrome de X frágil y epilepsia pediátrica PCDH19.
El precio actual de la acción Marinus Pharmaceuticals, Inc. en tiempo real es 8.11 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Hennessy Ad, Petrofac Ltd, Esports Technologies, Inc., Universal Logistics, BID CORP LTD y iShares Trust - iShares 5-10 Year Investment Grade Corporate Bond ETF. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
Industry: | Pharmaceuticals (NEC) |
Three Radnor Corporate Center
100 Matsonford Rd, Suite 304
RADNOR
PENNSYLVANIA 19087
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com